Mauro Iannopollo
Direttore Soc Oncologia Pistoia Pescia @Azienda Usl Toscana Centro
Signup · Get unlimited contacts
WORK HISTORY
Direttore Soc Oncologia Pistoia Pescia @Azienda Usl Toscana Centro
EDUCATION
Scuola Superiore Sant'Anna
Laurea , Medicina e Chirurgia
SDA Bocconi
Corso perfezionamento OMFT, Management in Oncologia
SDA Bocconi
Perfezionamento
Scuola Superiore Sant'Anna
Corso di Formazione, Corso di Formazione Manageriale per Dirigenti di Struttura Complessa e Aspiranti Direttori Sanitari
SDA Bocconi
Corsi Di Farmacoeconomia
Università di Pisa
Laurea , Medicina e Chirurgia
Università di Pisa
Corso di Master Universitario di 2° livello-CMU2, Sperimentazione clinica dei Farmaci
Università di Pisa
Specializzazione , Oncologia
ABOUT MAURO IANNOPOLLO
Director of Medical Oncology and Regional Secretary of CIPOMO (Tuscany), with 20+ years of clinical leadership and deep pharmaceutical expertise. I bridge clinical practice and corporate strategy, combining a high-impact oncological background with executive management training from SDA Bocconi. Core Value Proposition for Medical Affairs: Scientific & Strategic Leadership: Extensive experience in GOM tumor boards and ICI sequencing (NSCLC). Proven ability to translate clinical evidence into market adoption and therapeutic positioning. Market Access & Sustainability: Led 11+ Expanded Access Programs (EAP), delivering €1.1M in pharmaceutical cost avoidance for the NHS in 2025. Clinical Research & Governance: Principal Investigator for 10+ international trials; expert in GCP, regulatory science (Master in Clinical Drug Trials), and stakeholder management at regional institutional level. Academic Excellence: Alumnus of Scuola Superiore Sant\'Anna (Pisa), with 14 indexed publications (H-index 9). KOL Engagement & Medical Education: Active speaker and scientific chair at 50+ national and international congresses (ESMO, ASCO, IASLC, AIOM) on NSCLC, immunotherapy, and precision oncology. Recognized as scientific lead for educational programs sponsored by MSD, Roche, AstraZeneca, Novartis, Pfizer, Eli Lilly, and Bayer. Ready to bring this expertise into a Medical Director role, driving medical governance, cross-functional execution, and science-based stakeholder engagement at country level.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.